Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

biomarkers

Brain cancer glioblastoma

Tension expected as cancer market rises to $150bn-plus

IMS Health report anticipates increased demand for value-based pricing of oncology drugs

Daiichi Sankyo logo

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis

Eli Lilly HQ

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain

- PMLiVE

An effective commercial model for cancer care

Patient-centric cancer care

Celgene building

Celgene forms real-time, real-world trial partnership

Will collaborate with TriNetX, using its electronic medical records network

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear...

Blue Latitude Health

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

Sanofi reception

Sanofi hints at sweetened Medivation deal – or hostile bid

CEO Oliver Brandicourt claims “overwhelming support” for deal from shareholders

- PMLiVE

IMS Health to merge with Quintiles

Will create pharma services firm worth almost $18bn

Sanofi reception

Medivation unimpressed with Sanofi’s offer

CEO says the offer “substantially undervalues” the oncology specialist

- PMLiVE

Paywatch and the market access waters

Understanding and responding to payers’ needs has become priority number one for pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links